Johnson, director, sells Xeris Biopharma (XERS) shares for $786k

Published 15/08/2025, 22:02
Johnson, director, sells Xeris Biopharma (XERS) shares for $786k

John Johnson, a director of Xeris Biopharma Holdings Inc (NASDAQ:XERS), sold 107,500 shares of common stock on August 13, 2025, according to a recent SEC Filing. The stock has shown remarkable strength, gaining over 175% in the past year and currently trades near its 52-week high of $7.61. The shares were sold at a weighted average price of $7.3159, for a total value of $786459.

The prices for the sale ranged from $7.250 to $7.420. Following the transaction, Johnson directly owns 833,483 shares of Xeris Biopharma Holdings.

In other recent news, Xeris Pharmaceuticals reported impressive earnings for the second quarter of 2025, surpassing analyst expectations. The company posted an earnings per share (EPS) of -0.01, beating the forecasted -0.03. Additionally, Xeris achieved a revenue of $71.5 million, exceeding projections by 11.85%. These results have highlighted strong investor confidence in the company. In another development, H.C. Wainwright has assumed coverage of Xeris Pharmaceuticals with a Buy rating and set a price target of $10.00. The firm noted the stock’s significant performance, having risen 108% year to date in 2025. These recent developments underscore the growing interest and positive outlook from analysts and investors alike.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.